Abstract
Summary
Flupentixol has a strong antipsychotic effect, which is 4 ~ 8 times stronger than cloprothiazide, and the sedative effect is weaker.At the same time also anti - anxiety, anti - depression effect.Suitable for acute, chronic schizophrenia, depression and depressive neurosis.This product is easy to absorb, has first pass effect, through liver metabolism, kidney excretion.
LPI (LP Information)' newest research report, the “Flupentixol Industry Forecast” looks at past sales and reviews total world Flupentixol sales in 2022, providing a comprehensive analysis by region and market sector of projected Flupentixol sales for 2023 through 2029. With Flupentixol sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Flupentixol industry.
This Insight Report provides a comprehensive analysis of the global Flupentixol landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Flupentixol portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Flupentixol market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Flupentixol and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Flupentixol.
The global Flupentixol market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Flupentixol is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Flupentixol is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Flupentixol is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Flupentixol players cover H. Lundbeck, Sichuan Haisike Pharmaceutical, Chongqing Shenghuaxi Pharmaceutical, Chengdu Beite Pharmaceutical, Harbin Pharmaceutical Group, Hainan Yier Pharmaceutical, Shenzhen kangzhe Pharmaceutical and Sun Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Flupentixol market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Oral
Injection
Segmentation by application
Acute Phase
Consolidation Phase
Maintenance Phase
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
H. Lundbeck
Sichuan Haisike Pharmaceutical
Chongqing Shenghuaxi Pharmaceutical
Chengdu Beite Pharmaceutical
Harbin Pharmaceutical Group
Hainan Yier Pharmaceutical
Shenzhen kangzhe Pharmaceutical
Sun Pharmaceutical
LPI (LP Information)' newest research report, the “Flupentixol Industry Forecast” looks at past sales and reviews total world Flupentixol sales in 2022, providing a comprehensive analysis by region and market sector of projected Flupentixol sales for 2023 through 2029. With Flupentixol sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Flupentixol industry.
This Insight Report provides a comprehensive analysis of the global Flupentixol landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Flupentixol portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Flupentixol market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Flupentixol and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Flupentixol.
The global Flupentixol market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Flupentixol is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Flupentixol is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Flupentixol is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Flupentixol players cover H. Lundbeck, Sichuan Haisike Pharmaceutical, Chongqing Shenghuaxi Pharmaceutical, Chengdu Beite Pharmaceutical, Harbin Pharmaceutical Group, Hainan Yier Pharmaceutical, Shenzhen kangzhe Pharmaceutical and Sun Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Flupentixol market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Oral
Injection
Segmentation by application
Acute Phase
Consolidation Phase
Maintenance Phase
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
H. Lundbeck
Sichuan Haisike Pharmaceutical
Chongqing Shenghuaxi Pharmaceutical
Chengdu Beite Pharmaceutical
Harbin Pharmaceutical Group
Hainan Yier Pharmaceutical
Shenzhen kangzhe Pharmaceutical
Sun Pharmaceutical
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Flupentixol Market Size 2018-2029
2.1.2 Flupentixol Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Flupentixol Segment by Type
2.2.1 Oral
2.2.2 Injection
2.3 Flupentixol Market Size by Type
2.3.1 Flupentixol Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Flupentixol Market Size Market Share by Type (2018-2023)
2.4 Flupentixol Segment by Application
2.4.1 Acute Phase
2.4.2 Consolidation Phase
2.4.3 Maintenance Phase
2.5 Flupentixol Market Size by Application
2.5.1 Flupentixol Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Flupentixol Market Size Market Share by Application (2018-2023)
3 Flupentixol Market Size by Player
3.1 Flupentixol Market Size Market Share by Players
3.1.1 Global Flupentixol Revenue by Players (2018-2023)
3.1.2 Global Flupentixol Revenue Market Share by Players (2018-2023)
3.2 Global Flupentixol Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Flupentixol by Regions
4.1 Flupentixol Market Size by Regions (2018-2023)
4.2 Americas Flupentixol Market Size Growth (2018-2023)
4.3 APAC Flupentixol Market Size Growth (2018-2023)
4.4 Europe Flupentixol Market Size Growth (2018-2023)
4.5 Middle East & Africa Flupentixol Market Size Growth (2018-2023)
5 Americas
5.1 Americas Flupentixol Market Size by Country (2018-2023)
5.2 Americas Flupentixol Market Size by Type (2018-2023)
5.3 Americas Flupentixol Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Flupentixol Market Size by Region (2018-2023)
6.2 APAC Flupentixol Market Size by Type (2018-2023)
6.3 APAC Flupentixol Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Flupentixol by Country (2018-2023)
7.2 Europe Flupentixol Market Size by Type (2018-2023)
7.3 Europe Flupentixol Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Flupentixol by Region (2018-2023)
8.2 Middle East & Africa Flupentixol Market Size by Type (2018-2023)
8.3 Middle East & Africa Flupentixol Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Flupentixol Market Forecast
10.1 Global Flupentixol Forecast by Regions (2024-2029)
10.1.1 Global Flupentixol Forecast by Regions (2024-2029)
10.1.2 Americas Flupentixol Forecast
10.1.3 APAC Flupentixol Forecast
10.1.4 Europe Flupentixol Forecast
10.1.5 Middle East & Africa Flupentixol Forecast
10.2 Americas Flupentixol Forecast by Country (2024-2029)
10.2.1 United States Flupentixol Market Forecast
10.2.2 Canada Flupentixol Market Forecast
10.2.3 Mexico Flupentixol Market Forecast
10.2.4 Brazil Flupentixol Market Forecast
10.3 APAC Flupentixol Forecast by Region (2024-2029)
10.3.1 China Flupentixol Market Forecast
10.3.2 Japan Flupentixol Market Forecast
10.3.3 Korea Flupentixol Market Forecast
10.3.4 Southeast Asia Flupentixol Market Forecast
10.3.5 India Flupentixol Market Forecast
10.3.6 Australia Flupentixol Market Forecast
10.4 Europe Flupentixol Forecast by Country (2024-2029)
10.4.1 Germany Flupentixol Market Forecast
10.4.2 France Flupentixol Market Forecast
10.4.3 UK Flupentixol Market Forecast
10.4.4 Italy Flupentixol Market Forecast
10.4.5 Russia Flupentixol Market Forecast
10.5 Middle East & Africa Flupentixol Forecast by Region (2024-2029)
10.5.1 Egypt Flupentixol Market Forecast
10.5.2 South Africa Flupentixol Market Forecast
10.5.3 Israel Flupentixol Market Forecast
10.5.4 Turkey Flupentixol Market Forecast
10.5.5 GCC Countries Flupentixol Market Forecast
10.6 Global Flupentixol Forecast by Type (2024-2029)
10.7 Global Flupentixol Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 H. Lundbeck
11.1.1 H. Lundbeck Company Information
11.1.2 H. Lundbeck Flupentixol Product Offered
11.1.3 H. Lundbeck Flupentixol Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 H. Lundbeck Main Business Overview
11.1.5 H. Lundbeck Latest Developments
11.2 Sichuan Haisike Pharmaceutical
11.2.1 Sichuan Haisike Pharmaceutical Company Information
11.2.2 Sichuan Haisike Pharmaceutical Flupentixol Product Offered
11.2.3 Sichuan Haisike Pharmaceutical Flupentixol Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Sichuan Haisike Pharmaceutical Main Business Overview
11.2.5 Sichuan Haisike Pharmaceutical Latest Developments
11.3 Chongqing Shenghuaxi Pharmaceutical
11.3.1 Chongqing Shenghuaxi Pharmaceutical Company Information
11.3.2 Chongqing Shenghuaxi Pharmaceutical Flupentixol Product Offered
11.3.3 Chongqing Shenghuaxi Pharmaceutical Flupentixol Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Chongqing Shenghuaxi Pharmaceutical Main Business Overview
11.3.5 Chongqing Shenghuaxi Pharmaceutical Latest Developments
11.4 Chengdu Beite Pharmaceutical
11.4.1 Chengdu Beite Pharmaceutical Company Information
11.4.2 Chengdu Beite Pharmaceutical Flupentixol Product Offered
11.4.3 Chengdu Beite Pharmaceutical Flupentixol Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Chengdu Beite Pharmaceutical Main Business Overview
11.4.5 Chengdu Beite Pharmaceutical Latest Developments
11.5 Harbin Pharmaceutical Group
11.5.1 Harbin Pharmaceutical Group Company Information
11.5.2 Harbin Pharmaceutical Group Flupentixol Product Offered
11.5.3 Harbin Pharmaceutical Group Flupentixol Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Harbin Pharmaceutical Group Main Business Overview
11.5.5 Harbin Pharmaceutical Group Latest Developments
11.6 Hainan Yier Pharmaceutical
11.6.1 Hainan Yier Pharmaceutical Company Information
11.6.2 Hainan Yier Pharmaceutical Flupentixol Product Offered
11.6.3 Hainan Yier Pharmaceutical Flupentixol Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Hainan Yier Pharmaceutical Main Business Overview
11.6.5 Hainan Yier Pharmaceutical Latest Developments
11.7 Shenzhen kangzhe Pharmaceutical
11.7.1 Shenzhen kangzhe Pharmaceutical Company Information
11.7.2 Shenzhen kangzhe Pharmaceutical Flupentixol Product Offered
11.7.3 Shenzhen kangzhe Pharmaceutical Flupentixol Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Shenzhen kangzhe Pharmaceutical Main Business Overview
11.7.5 Shenzhen kangzhe Pharmaceutical Latest Developments
11.8 Sun Pharmaceutical
11.8.1 Sun Pharmaceutical Company Information
11.8.2 Sun Pharmaceutical Flupentixol Product Offered
11.8.3 Sun Pharmaceutical Flupentixol Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Sun Pharmaceutical Main Business Overview
11.8.5 Sun Pharmaceutical Latest Developments
12 Research Findings and Conclusion